Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. - Wikidata - wikimedia - TriplyDB

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer.

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer.

http://www.wikidata.org/entity/Q45309107

about

Regulation of ERBB3/HER3 signaling in cancer Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer.Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer.Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment.Pregnancy complicated by obesity induces global transcript expression alterations in visceral and subcutaneous fat.Eph receptors and ephrins in cancer: bidirectional signalling and beyond.ALK-activating homologous mutations in LTK induce cellular transformation.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?The role of gene expression profiling in early-stage non-small cell lung cancer.Profiling Eph receptor expression in cells and tissues: a targeted mass spectrometry approach Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction.WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling The ERBB3 receptor in cancer and cancer gene therapy Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer.Loss of the EPH receptor B6 contributes to colorectal cancer metastasis Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.Genetic and epigenetic changes in lung carcinoma and their clinical implications.Dancing with the dead: Eph receptors and their kinase-null partners.The Eph/Ephrin family in cancer metastasis: communication at the service of invasion.The promise of anti-ErbB3 monoclonals as new cancer therapeutics Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.HER3 as a Therapeutic Target in Cancer.Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue.Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy The prospect of patritumab for treating non-small cell lung cancer.Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling.Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.Epigenetic regulation of glucose transporters in non-small cell lung cancer.Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.ERBB3 as an independent prognostic marker for nasopharyngeal carcinoma.

P2860

Q27024334-917C1077-F714-4397-A8D7-DDC42CDF1999 Q27853182-5D5B91D8-E375-40A4-A7B8-5ED192A3D686 Q30315828-B3D786E8-4776-46B7-A796-969E9914DCF8 Q30528942-D1D7EEEF-D67D-443B-9097-5C2F8E465CDF Q33251998-16E9A19F-8D7C-49EB-9AC3-F067E5264A1C Q33412770-7D0FB7AA-E2BB-42F9-BA8A-E759016BA060 Q33732190-011B9E18-A9E3-4036-845A-3651AF35E8E8 Q33890597-EF59E17C-7699-425C-8AAA-7495F5310151 Q33910532-D2FB3F91-F3C6-49E2-99E5-F7F9DB169AC0 Q33954314-8079D205-3328-4C9B-8ADA-0507983EB1E5 Q34021365-97AA0095-EB88-4DEF-B9A6-9679F7AF87D2 Q34162940-A672F273-5C5D-4BE2-B2E2-374C74BA37F1 Q34983846-9D99B6C8-A70B-4746-A4AB-142E7D31A19E Q35667675-0F375AEB-BBC0-40BC-8160-4A66D46F6EBD Q36402707-9B353F12-B2A0-4CC7-9EEF-A1DECD3D7AB7 Q36615223-B4CDEDD1-397C-4768-81D9-9092F770DAF4 Q37124053-679FDCEE-8C19-4B89-A739-02D404AAE806 Q37135372-EC33D0EA-DE46-4D60-9435-2B82A5F821BC Q37375251-8070298A-7BCE-483E-90D8-60CF3E68455D Q37389768-3E691BB1-6CE0-49B6-B061-0850D85E3FD3 Q37580359-E4A2F948-FB06-47B6-8B9B-A47F32201CA5 Q37589161-0FAD432D-838C-40B6-99BA-BCF725B37C88 Q37681807-FC41EEED-4444-458B-B640-1392144E1253 Q37692080-FF918EE5-4797-45D9-ADC2-33237EC0D730 Q37855515-414D46E3-985D-4688-B1B4-2B815C9EEC9D Q37860149-8157FF65-EE4B-4CC4-9FD8-BA9C798935B9 Q38006838-77656F20-54F9-462D-B0FA-FE9484E030A2 Q38034347-B8717339-F6DF-49EE-BA63-E4EA46F85D53 Q38390565-0066A4E2-B24E-4001-8B0D-D8C42F68F279 Q38725101-2B9EE37E-1FCE-43DE-AAAF-2E3F0420C0EA Q38806218-482561A1-9830-426E-A972-1DB7FCF8554C Q38945259-9CB84134-D562-450E-ADA2-1EB8D751441A Q38981780-123ED2D9-6547-4760-A96B-27BE995F9737 Q39005693-2682E25E-3A3C-4E1D-9158-5882B59096B1 Q39308117-5E06C99A-FB12-4118-84BD-FE95E854A502 Q39431398-32CD1262-E037-4D62-80F2-BFD3AE5A3216 Q40289611-0E291B6B-4B84-40F7-ADE8-EA100D34AF52 Q42576918-16A117BB-BEB1-4A84-8D38-E59941F38630 Q42738385-6789BE3E-F057-4C32-B8CB-A3D139E6B69D Q44449930-8EBA1358-8782-47DC-9698-8C73A345A98A

P2860

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer.

http://www.wikidata.org/entity/Q45309107

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Identification of metastasis-a ...... in non-small cell lung cancer.

@en

Identification of metastasis-a ...... in non-small cell lung cancer.

@nl

type

label

Identification of metastasis-a ...... in non-small cell lung cancer.

@en

Identification of metastasis-a ...... in non-small cell lung cancer.

@nl

prefLabel

Identification of metastasis-a ...... in non-small cell lung cancer.

@en

Identification of metastasis-a ...... in non-small cell lung cancer.

@nl

P1433

Q45309107-811577E4-538A-420A-8A15-F52ECF2D2E2C

P1476

Q45309107-7B637195-EA9C-4E4C-8EBB-756F94947968

P2093

Q45309107-080A7BBE-C0AC-47BF-857A-1277B70992E2

Q45309107-21862244-56AD-4D9D-BDA1-8E6C39C9632B

Q45309107-2984FCB1-C0EE-4010-84A7-BE011FD81D57

Q45309107-523A8A3E-D3F2-4D31-8D02-A4922C46848A

Q45309107-563073AE-16E2-4F6D-AD07-08EC31A71910

Q45309107-60AD8F50-75DE-4A8B-9C7E-453947BA9CF4

Q45309107-7A56DC08-C9E9-4288-9B4E-20D05738952F

Q45309107-82569124-4B5A-49DE-93C3-A9AE7E0F96A5

Q45309107-9B918172-332B-4EAA-81EE-434E6B592CA3

Q45309107-A2019C01-BF08-49BB-97F8-F805EFEC3FE1

P304

Q45309107-F589F0C2-69E2-4003-AB3E-6F74FB45638F

P31

Q45309107-7604D434-E14F-4C5E-9D27-0E21738B0D50

P356

Q45309107-351E981C-A4E2-49B4-A3A0-2FBFB944BD78

P407

Q45309107-3838718F-E0F5-45FB-B313-00BBD3C539DE

P433

Q45309107-5F83B479-F858-4867-8533-885994F60E45

P478

Q45309107-F6866D8E-C9B4-4FA3-8241-EE986AFE8ADD

P50

Q45309107-0F52ED63-ACD3-4128-8818-86FF97EA6AD4

Q45309107-5CA12385-8368-4157-8FAA-CD71ECCCB49E

P577

Q45309107-63377F56-6E66-4E9A-B10C-80CFA990F33B

P698

Q45309107-26CACE0F-1392-493F-A416-08F583BC1559

P356

0008-5472.CAN-04-3388

P1433

Cancer Research

P1476

Identification of metastasis-a ...... in non-small cell lung cancer.

@en

P2093

Björn Steffen

http://www.w3.org/2001/XMLSchema#string

Christian H Brandts

http://www.w3.org/2001/XMLSchema#string

Etmar Bulk

http://www.w3.org/2001/XMLSchema#string

Hubert Serve

http://www.w3.org/2001/XMLSchema#string

Joachim Schwäble

http://www.w3.org/2001/XMLSchema#string

Michael Thomas

http://www.w3.org/2001/XMLSchema#string

Paul M Schneider

http://www.w3.org/2001/XMLSchema#string

Ralf Metzger

http://www.w3.org/2001/XMLSchema#string

Sylvia Plewka

http://www.w3.org/2001/XMLSchema#string

Thorsten Pohle

http://www.w3.org/2001/XMLSchema#string

P304

1778-1782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-04-3388

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Carsten Müller-Tidow

Sven Diederichs

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15753374

http://www.w3.org/2001/XMLSchema#string